Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04737187 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
A Phase 3 study of Refractory Metastatic Colorectal Cancer, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 492
- Enrollment target
- 20
- Study locations
NCT04737187 is a Phase 3 study of Refractory Metastatic Colorectal Cancer that has completed, run by Taiho Oncology. The registered enrollment target is 492 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT04737187, a Phase 3 study of Refractory Metastatic Colorectal Cancer, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 492 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Trifluridine/Tipiracil
Study Locations (20)
Other
- "Medizinische Universität Graz " - Graz
- "Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V" - Innsbruck
- "Ordensklinikum Linz Barmherzige Schwestern Interne I" - Linz
- "Landeskrankenhaus Feldkirch Interne E" - Rankweil
- "Landeskrankenhaus (SALK) Universitätsklinik für Innere Medizin III (SALK)" - Salzburg
- "Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie" - Vienna
- "Landesklinikum Wiener Neustadt " - Wiener Neustadt
- "OLV Ziekenhuis Oncology" - Aalst
California
- City of Hope - Duarte
- City of Hope - South Pasedena - South Pasadena
- City of Hope - Upland - Upland
Florida
- Mayo Clinic - FL - Jacksonville
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Comprehensive Hematology Oncology - St. Petersburg
Arizona
- Mayo Clinic Hospital - Phoenix
Illinois
- DuPage Medical Group - Joliet Oncology-Hematology Associates - Joliet
Indiana
- Investigative Clinical Research of Indiana LLC - Noblesville
Nebraska
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Omaha
New York
- Mayo Clinic - Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2020-11-25 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04737187
The ClinicalTrials.gov registry entry for NCT04737187 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 492 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT04737187 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04737187 about?
NCT04737187 is a clinical study titled "Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients". This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC.
What is the current status of trial NCT04737187?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 492 participants. The study started on 2020-11-25. Estimated completion is 2023-09-12.
What conditions does trial NCT04737187 study?
This clinical trial studies the following conditions: Refractory Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT04737187?
The interventions under investigation include: Bevacizumab (DRUG), Trifluridine/Tipiracil (DRUG).
Who is sponsoring clinical trial NCT04737187?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04737187 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.